Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Prog Cell Cycle Res. 2003;5:269-78.

Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.

Author information

  • 1Chemical Genetics Laboratory, RIKEN, Saitama, Japan.

Abstract

It is becoming increasingly clear that reversible acetylation of proteins is a signal directly controlling the activity of key cellular regulators. The enzymes controlling protein acetylation were identified as histone acetyltransferases (HATs) and histone deacetylases (HDACs). Following the discovery of HATs and HDACs, a number of non-histone proteins have been identified as substrates for these enzymes. HDACs play important roles in transcriptional regulation and pathogenesis of cancer through removing acetyl groups from histones and other transcriptional regulators. HDAC inhibitors case cell cycle arrest, differentiation and/or apoptosis of many tumors, suggesting their usefulness for chemotherapy and differentiation therapy. Since recent studies have revealed that HDACs are structurally and functionally diverse, it should be possible to develop inhibitors specific to individual HDACs as more promising agents for cancer therapy.

PMID:
14593721
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk